Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: A multicenter, double-blind, randomized controlled study

Yoichi Ichikawa, Terunobu Saito, Haisashi Yamanaka, Masashi Akizuki, Hirobumi Kondo, Shigeto Kobayashi, Hisaji Oshima, Shinichi Kawai, Nobuaki Hama, Hidehiro Yamada, Tsuneyo Mimori, Koichi Amano, Yasushi Tanaka, Yasuo Matsuoka, Sumiki Yamamoto, Tsukasa Matsubara, Norikazu Murata, Tomiaki Asai, Yasuo Suzuki, Yutaka OkanoTouru Akaboshi, Takao Fujii, Michito Hirakata, Takahiro Suzuki, Nobuo Takubo, Yasuyuki Miyata, Yukio Sato, Norihiro Nishimoto, Eizo Saito, Shigemasa Sawada, Akira Rikimaru, Hajime Yamagata, Shigeto Toma, Katsumi Ito, Katsumi Yoshida

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Disease-modifying antirheumatic drug (DMARD) combination therapies are used widely, but there have been few reports clearly demonstrating that combination therapy is more effective than DMARD monotherapy. We conducted a multicenter, double-blind controlled trial in order to clarify that the combination of methotrexate and bucillamine is more effective than either alone. The subjects of this study were 71 patients with active rheumatoid arthritis within 2 years of onset. Dosages were 8mg methotrexate with 5 mg folic acid per week (MTX group), 200 mg bucillamine per day (BUC group), or both MTX and BUC (combination group). Clinical effects and adverse reactions were observed for 96 weeks. The ACR 20 response rate was 79.2% in the combination group, significantly higher than the rates of 43.5% for the MTX group (P = 0.008) and 45.8% for the BUC group (P = 0.0178). The cumulative survival curve of maintaining the ACR 20 response was significantly higher in the combination group than in the MTX and BUC groups (P = 0.0123 and P = 0.0088, respectively). The mean increase in the total Sharp score over 96 weeks was 12.6 ± 9.0 in the combination group, significantly lower (P = 0.0468) than the value of 28.0 ± 28.3 for the single DMARD (combined MTX and BUC) group. The incidence of adverse reactions did not differ significantly between the three groups. It was concluded that the combination therapy with MTX and BUC showed significantly higher clinical efficacy than either of the single DMARD therapies.

Original languageEnglish
Pages (from-to)323-328
Number of pages6
JournalModern Rheumatology
Volume15
Issue number5
DOIs
Publication statusPublished - 2005 Oct

Fingerprint

Antirheumatic Agents
Therapeutic Uses
Methotrexate
Rheumatoid Arthritis
Drug Therapy
Drug Combinations
Folic Acid
Survival
bucillamine
Incidence
Therapeutics

Keywords

  • Bucillamine
  • Combination therapy
  • Methotrexate
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis : A multicenter, double-blind, randomized controlled study. / Ichikawa, Yoichi; Saito, Terunobu; Yamanaka, Haisashi; Akizuki, Masashi; Kondo, Hirobumi; Kobayashi, Shigeto; Oshima, Hisaji; Kawai, Shinichi; Hama, Nobuaki; Yamada, Hidehiro; Mimori, Tsuneyo; Amano, Koichi; Tanaka, Yasushi; Matsuoka, Yasuo; Yamamoto, Sumiki; Matsubara, Tsukasa; Murata, Norikazu; Asai, Tomiaki; Suzuki, Yasuo; Okano, Yutaka; Akaboshi, Touru; Fujii, Takao; Hirakata, Michito; Suzuki, Takahiro; Takubo, Nobuo; Miyata, Yasuyuki; Sato, Yukio; Nishimoto, Norihiro; Saito, Eizo; Sawada, Shigemasa; Rikimaru, Akira; Yamagata, Hajime; Toma, Shigeto; Ito, Katsumi; Yoshida, Katsumi.

In: Modern Rheumatology, Vol. 15, No. 5, 10.2005, p. 323-328.

Research output: Contribution to journalArticle

Ichikawa, Y, Saito, T, Yamanaka, H, Akizuki, M, Kondo, H, Kobayashi, S, Oshima, H, Kawai, S, Hama, N, Yamada, H, Mimori, T, Amano, K, Tanaka, Y, Matsuoka, Y, Yamamoto, S, Matsubara, T, Murata, N, Asai, T, Suzuki, Y, Okano, Y, Akaboshi, T, Fujii, T, Hirakata, M, Suzuki, T, Takubo, N, Miyata, Y, Sato, Y, Nishimoto, N, Saito, E, Sawada, S, Rikimaru, A, Yamagata, H, Toma, S, Ito, K & Yoshida, K 2005, 'Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: A multicenter, double-blind, randomized controlled study', Modern Rheumatology, vol. 15, no. 5, pp. 323-328. https://doi.org/10.1007/s10165-005-0420-z
Ichikawa, Yoichi ; Saito, Terunobu ; Yamanaka, Haisashi ; Akizuki, Masashi ; Kondo, Hirobumi ; Kobayashi, Shigeto ; Oshima, Hisaji ; Kawai, Shinichi ; Hama, Nobuaki ; Yamada, Hidehiro ; Mimori, Tsuneyo ; Amano, Koichi ; Tanaka, Yasushi ; Matsuoka, Yasuo ; Yamamoto, Sumiki ; Matsubara, Tsukasa ; Murata, Norikazu ; Asai, Tomiaki ; Suzuki, Yasuo ; Okano, Yutaka ; Akaboshi, Touru ; Fujii, Takao ; Hirakata, Michito ; Suzuki, Takahiro ; Takubo, Nobuo ; Miyata, Yasuyuki ; Sato, Yukio ; Nishimoto, Norihiro ; Saito, Eizo ; Sawada, Shigemasa ; Rikimaru, Akira ; Yamagata, Hajime ; Toma, Shigeto ; Ito, Katsumi ; Yoshida, Katsumi. / Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis : A multicenter, double-blind, randomized controlled study. In: Modern Rheumatology. 2005 ; Vol. 15, No. 5. pp. 323-328.
@article{b61ba1581126499e819d40d5b92b15cb,
title = "Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: A multicenter, double-blind, randomized controlled study",
abstract = "Disease-modifying antirheumatic drug (DMARD) combination therapies are used widely, but there have been few reports clearly demonstrating that combination therapy is more effective than DMARD monotherapy. We conducted a multicenter, double-blind controlled trial in order to clarify that the combination of methotrexate and bucillamine is more effective than either alone. The subjects of this study were 71 patients with active rheumatoid arthritis within 2 years of onset. Dosages were 8mg methotrexate with 5 mg folic acid per week (MTX group), 200 mg bucillamine per day (BUC group), or both MTX and BUC (combination group). Clinical effects and adverse reactions were observed for 96 weeks. The ACR 20 response rate was 79.2{\%} in the combination group, significantly higher than the rates of 43.5{\%} for the MTX group (P = 0.008) and 45.8{\%} for the BUC group (P = 0.0178). The cumulative survival curve of maintaining the ACR 20 response was significantly higher in the combination group than in the MTX and BUC groups (P = 0.0123 and P = 0.0088, respectively). The mean increase in the total Sharp score over 96 weeks was 12.6 ± 9.0 in the combination group, significantly lower (P = 0.0468) than the value of 28.0 ± 28.3 for the single DMARD (combined MTX and BUC) group. The incidence of adverse reactions did not differ significantly between the three groups. It was concluded that the combination therapy with MTX and BUC showed significantly higher clinical efficacy than either of the single DMARD therapies.",
keywords = "Bucillamine, Combination therapy, Methotrexate, Rheumatoid arthritis",
author = "Yoichi Ichikawa and Terunobu Saito and Haisashi Yamanaka and Masashi Akizuki and Hirobumi Kondo and Shigeto Kobayashi and Hisaji Oshima and Shinichi Kawai and Nobuaki Hama and Hidehiro Yamada and Tsuneyo Mimori and Koichi Amano and Yasushi Tanaka and Yasuo Matsuoka and Sumiki Yamamoto and Tsukasa Matsubara and Norikazu Murata and Tomiaki Asai and Yasuo Suzuki and Yutaka Okano and Touru Akaboshi and Takao Fujii and Michito Hirakata and Takahiro Suzuki and Nobuo Takubo and Yasuyuki Miyata and Yukio Sato and Norihiro Nishimoto and Eizo Saito and Shigemasa Sawada and Akira Rikimaru and Hajime Yamagata and Shigeto Toma and Katsumi Ito and Katsumi Yoshida",
year = "2005",
month = "10",
doi = "10.1007/s10165-005-0420-z",
language = "English",
volume = "15",
pages = "323--328",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",
number = "5",

}

TY - JOUR

T1 - Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis

T2 - A multicenter, double-blind, randomized controlled study

AU - Ichikawa, Yoichi

AU - Saito, Terunobu

AU - Yamanaka, Haisashi

AU - Akizuki, Masashi

AU - Kondo, Hirobumi

AU - Kobayashi, Shigeto

AU - Oshima, Hisaji

AU - Kawai, Shinichi

AU - Hama, Nobuaki

AU - Yamada, Hidehiro

AU - Mimori, Tsuneyo

AU - Amano, Koichi

AU - Tanaka, Yasushi

AU - Matsuoka, Yasuo

AU - Yamamoto, Sumiki

AU - Matsubara, Tsukasa

AU - Murata, Norikazu

AU - Asai, Tomiaki

AU - Suzuki, Yasuo

AU - Okano, Yutaka

AU - Akaboshi, Touru

AU - Fujii, Takao

AU - Hirakata, Michito

AU - Suzuki, Takahiro

AU - Takubo, Nobuo

AU - Miyata, Yasuyuki

AU - Sato, Yukio

AU - Nishimoto, Norihiro

AU - Saito, Eizo

AU - Sawada, Shigemasa

AU - Rikimaru, Akira

AU - Yamagata, Hajime

AU - Toma, Shigeto

AU - Ito, Katsumi

AU - Yoshida, Katsumi

PY - 2005/10

Y1 - 2005/10

N2 - Disease-modifying antirheumatic drug (DMARD) combination therapies are used widely, but there have been few reports clearly demonstrating that combination therapy is more effective than DMARD monotherapy. We conducted a multicenter, double-blind controlled trial in order to clarify that the combination of methotrexate and bucillamine is more effective than either alone. The subjects of this study were 71 patients with active rheumatoid arthritis within 2 years of onset. Dosages were 8mg methotrexate with 5 mg folic acid per week (MTX group), 200 mg bucillamine per day (BUC group), or both MTX and BUC (combination group). Clinical effects and adverse reactions were observed for 96 weeks. The ACR 20 response rate was 79.2% in the combination group, significantly higher than the rates of 43.5% for the MTX group (P = 0.008) and 45.8% for the BUC group (P = 0.0178). The cumulative survival curve of maintaining the ACR 20 response was significantly higher in the combination group than in the MTX and BUC groups (P = 0.0123 and P = 0.0088, respectively). The mean increase in the total Sharp score over 96 weeks was 12.6 ± 9.0 in the combination group, significantly lower (P = 0.0468) than the value of 28.0 ± 28.3 for the single DMARD (combined MTX and BUC) group. The incidence of adverse reactions did not differ significantly between the three groups. It was concluded that the combination therapy with MTX and BUC showed significantly higher clinical efficacy than either of the single DMARD therapies.

AB - Disease-modifying antirheumatic drug (DMARD) combination therapies are used widely, but there have been few reports clearly demonstrating that combination therapy is more effective than DMARD monotherapy. We conducted a multicenter, double-blind controlled trial in order to clarify that the combination of methotrexate and bucillamine is more effective than either alone. The subjects of this study were 71 patients with active rheumatoid arthritis within 2 years of onset. Dosages were 8mg methotrexate with 5 mg folic acid per week (MTX group), 200 mg bucillamine per day (BUC group), or both MTX and BUC (combination group). Clinical effects and adverse reactions were observed for 96 weeks. The ACR 20 response rate was 79.2% in the combination group, significantly higher than the rates of 43.5% for the MTX group (P = 0.008) and 45.8% for the BUC group (P = 0.0178). The cumulative survival curve of maintaining the ACR 20 response was significantly higher in the combination group than in the MTX and BUC groups (P = 0.0123 and P = 0.0088, respectively). The mean increase in the total Sharp score over 96 weeks was 12.6 ± 9.0 in the combination group, significantly lower (P = 0.0468) than the value of 28.0 ± 28.3 for the single DMARD (combined MTX and BUC) group. The incidence of adverse reactions did not differ significantly between the three groups. It was concluded that the combination therapy with MTX and BUC showed significantly higher clinical efficacy than either of the single DMARD therapies.

KW - Bucillamine

KW - Combination therapy

KW - Methotrexate

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=27744516900&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744516900&partnerID=8YFLogxK

U2 - 10.1007/s10165-005-0420-z

DO - 10.1007/s10165-005-0420-z

M3 - Article

C2 - 17029087

AN - SCOPUS:27744516900

VL - 15

SP - 323

EP - 328

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

IS - 5

ER -